首页|17β-estradiol配伍DRSP对绝经综合征患者血清FSH及E2调控作用

17β-estradiol配伍DRSP对绝经综合征患者血清FSH及E2调控作用

扫码查看
目的 研究17β-estradiol配伍DRSP治疗绝经综合征患者血清FSH及E2调控作用.方法 选取2013年11月~2016年11月在丽水市人民医院接受治疗的绝经综合征的女性患者共90例.随机将患者分为3组,17β组(30例,单独使用17β-estradiol治疗)、DRSP组(30例,单独使用DRSP治疗)、联合组(30例,17β-estradiol结合DRSP治疗).使用Kupperman的绝经综合征的评测法,对患者的身体症状量化,治疗后对患者进行比较分析,观察3组患者的治疗有效率情况,患者在治疗前进行的检查项目包含肝肾功能、血尿常规、空腹时血糖含量、卵泡刺激素(follicle-stimulating hormone,FSH)、E2、低密度脂蛋白(low-density lipoprotein,LDL)、总胆固醇(total cholesterol,TC)、心电图、腔内的多普勒超声、乳腺的彩超、高密度脂蛋白(high-density lipoprotein,HDL)等,治疗前按照Kupperman评测表评价一次,在每个疗程结束后再测量一次,并在此进行上述的各项检查.结果 联合组患者在治疗后,除了皮肤上的蚁走感和治疗前没有差异以外,其他的症状的积分差异均都统计学的意义,其中性交痛、头痛、身体感觉异常、容易激动、心悸、关节痛、疲乏、失眠和潮热的症状评分差异显著(P<0.01),DRSP组患者在治疗后,性交痛、抑郁和失眠有所改善,差异有统计学意义(P<0.05),其他症状均无明显改善;17β组患者在治疗后,头痛、关节疼痛和失眠有所改善,差异有统计学意义(P<0.05),其他症状均无明显改善;联合组的总有效率为90.0%,DRSP组的总有效率为73.33%,17β组的总有效率为70.0%,联合组与另外量组对比差异显著(P<0.05),治疗前后联合组患者在血TC、E2和FSH对比中差异显著(P<0.05),DRSP组患者FSH在治疗前后有差异,其他均无差异,17β组患者E2在治疗前后有差异,其他均无差异.结论 17β-estradiol配伍DRSP治疗绝经综合征患者取得了良好的临床疗效,其体内血清FSH及E2调控作用显著.
Effect of 17β-estradiol combined with DRSP on serum FSH and E2 in patients with menopausal
Objective To study the regulation of serum FSH and E2 in the treatment of menopausal syndrome with 17 beta estradiol combined with DRSP. Methods A total of 90 female patients with menopausal syndrome treated in our hospital from November 2013 to November 2016 were selected. The patients were randomly divided into three groups: 17β group (30 patients, 17β-estradiol alone), DRSP group (30 patients treated with DRSP alone) and 30 patients (17β-estradiol combined with DRSP). Kupperman's menopausal syndrome was used to evaluate the physical symptoms of the patients and to compare the patients after the treatment. The patients' treatment efficiency was observed. The items examined before treatment included liver and kidney function, hematuria routine , Fasting blood glucose, FSH, E2, LDL, blood TC, electrocardiogram, intracavitary Doppler ultrasound, breast ultrasound, HDL, Kupperman evaluation table in accordance with the evaluation before the end of each treatment measure again, And performs the above-mentioned inspection. Results In the combined group, there was no significant difference in the scores of other symptoms except the differences between the ants on the skin and the treatment before treatment. There were significant differences in the scores of pain, headache, body sensation, agitation, palpitation, Pain, fatigue, insomnia and hot flashes were significantly different (P<0.01). In the DRSP group, pain, depression and insomnia were improved after treatment (P<0.05), other symptoms were (P<0.05), other symptoms were not improved;the total effective rate of combined group was 90.0%, DRSP (P<0.05), and the total effective rate of the group was significantly higher than that of the control group (P<0.05) .There was no significant difference The total effective rate was 73.33% in the group and 70.0% in the 17β group. There was significant difference between the combined group and the other groups (P<0.05). The difference of TC, E2 and FSH in the combined group before and after treatment (P<0.05). There was no difference in FSH between the two groups before and after treatment. There was no difference between the two groups before and after treatment. Conclusion 17β-estradiol combined with DRSP in the treatment of menopausal syndrome patients achieved good clinical effect, the serum levels of FSH and E2 in the body is significant.

17β-estradiolDRSPmenopausal syndrome

吴红莲、黄志华、王小尚

展开 >

丽水市人民医院 妇产科,浙江 丽水 323000

17β-雌二醇 DRSP 17β-estradiol配伍DRSP 绝经综合征

浙江省医药卫生一般研究计划

2011RCB010

2017

中国生化药物杂志
南京生物化学制药研究所,全国生化制药情报中心站,中国生化制药工业协会,中国药品生物制品检定所

中国生化药物杂志

ISSN:1005-1678
年,卷(期):2017.37(1)
  • 1